Magazine Article | July 1, 2021

Companies To Watch: NervGen Pharma

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Beyond preclinicals to human trials: a drug that could repair and regrow neurons


NervGen Pharma is a public company in Canada developing drugs to repair nerve damage and neurodegeneration by inhibiting protein tyrosine phosphatase sigma (PTP σ), a key component of the neural-death cascade, to promote nerve regeneration, remyelination, and increased neuroplasticity. Its lead product, coded NVG-291, is a peptide mimetic compound with wide potential for treating numerous neurological conditions. NVG-291 is about to enter a Phase 1 dose-escalation trial prior to planned clinical development for spinal-cord injury, MS, and Alzheimer’s disease.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader